Page 16 - கூட்டணி க்கு பெருவாரியாக பரவும் தொற்று நோய் ப்ரிப்யாரெட்நெஸ் கண்டுபிடிப்பு News Today : Breaking News, Live Updates & Top Stories | Vimarsana
UN-backed program seeks rollout of 100M vaccine doses in Q1 washingtonpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from washingtonpost.com Daily Mail and Mail on Sunday newspapers.
Study finds COVID-19 vaccine may reduce virus transmission
What to expect after getting a COVID-19 vaccine By Associated Press | February 3, 2021 at 11:09 AM CST - Updated February 3 at 9:18 PM
(AP) - AstraZeneca’s COVID-19 vaccine shows a hint that it may reduce transmission of the virus and offers strong protection for three months on just a single dose, researchers said Wednesday in an encouraging turn in the campaign to suppress the outbreak.
The preliminary findings from Oxford University, a co-developer of the vaccine, could vindicate the British government’s controversial strategy of delaying the second shot for up to 12 weeks so that more people can be quickly given a first dose. Up to now, the recommended time between doses has been four weeks.
The COVAX initiative for equitable global access to COVID-19 vaccines has published its first distribution list, planning enough doses for dozens of countries to immunise more than 3 percent of their populations by mid-year.
The release of the “interim distribution forecast” on Wednesday came amid concerns over whether lower-income countries will be left out of the immunisation race dominated by rich nations – a problem COVAX, which is led by the United Nations-backed vaccine alliance Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI) and the World Health Organization (WHO), was set up to resolve.
The list broke down for the first time how the programme’s initial 337.2 million doses will be distributed, in line with a target “to protect the most vulnerable groups such as health care workers” in the first half of the year.
<div class="at-above-post addthis tool" data-url="https://www.metro.us/novavax-says-covid-19-vaccine/"></div>CHICAGO (Reuters) – Novavax Inc said on Thursday its coronavirus vaccine was 89.3% effective in preventing COVID-19 in a trial conducted in the United Kingdom, and was nearly as effective in protecting against the more highly contagious variant first discovered in the UK, according to a preliminary analysis. A mid-stage trial of the vaccine in […]<! AddThis Advanced Settings above via filter on get the excerpt ><! AddThis Advanced Settings below via filter on get the excerpt ><! AddThis Advanced Settings generic via filter on get the excerpt ><! AddThis Share Buttons above via filter on get the excerpt ><! AddThis Share Buttons below via filter on get the excerpt ><div class="at-below-post addthis tool" data-url="https://www.metro.us/novavax-says-covid-19-vaccine/"><
Novavax Inc said on Thursday its coronavirus vaccine was 89.3% effective in preventing COVID-19 in a trial conducted in the United Kingdom, and was nearly as effective in protecting against the more highly contagious variant first discovered in the UK, according to a preliminary analysis.